Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - ARCA biopharma, Inc. | d570309dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 17, 2013 (July 17, 2013)
ARCA biopharma, Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 000-22873 | 36-3855489 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
8001 Arista Place, Suite 430, Broomfield, CO 80021
(Address of Principal Executive Offices) (Zip Code)
(720) 940-2200
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 — Other Events
Item 8.01. Other Events.
On July 17, 2013, ARCA biopharma, Inc. provided a general business update and clinical development guidance. The press release is furnished as Exhibit 99.1 hereto, the contents of which are incorporated herein by reference.
Section 9 — Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press Release titled “ARCA biopharma Provides Business Update; GENETIC-AF Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Planned to Begin Patient Enrollment in Q1 2014; ARCA and Medtronic, Inc. Are Collaborating on Phase 2B Portion of GENETIC-AF”. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: July 17, 2013
| ARCA biopharma, Inc. (Registrant) | ||
| By: | /s/ Christopher D. Ozeroff | |
| Name: | Christopher D. Ozeroff | |
| Title: | SVP and General Counsel | |
INDEX TO EXHIBITS
| Exhibit |
Description | |
| 99.1 | Press Release titled “ARCA biopharma Provides Business Update; GENETIC-AF Trial Evaluating Gencaro as Potential Treatment for Atrial Fibrillation Planned to Begin Patient Enrollment in Q1 2014; ARCA and Medtronic, Inc. Are Collaborating on Phase 2B Portion of GENETIC-AF”. | |